Kyverna Therapeutics, Inc. KYTX Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Finance Lease, Right-of-Use Asset, after Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAsset.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s finance lease, right-of-use asset, after accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s finance lease, right-of-use asset, after accumulated amortization?
- Kyverna Therapeutics, Inc. (KYTX) reported finance lease, right-of-use asset, after accumulated amortization of $198K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s finance lease, right-of-use asset, after accumulated amortization changed year-over-year?
- Kyverna Therapeutics, Inc.'s finance lease, right-of-use asset, after accumulated amortization decreased by 67.2% year-over-year, from $603K to $198K.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s finance lease, right-of-use asset, after accumulated amortization?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s finance lease, right-of-use asset, after accumulated amortization has grown at a -58.7% compound annual growth rate (CAGR), from $1.79M to $305K.